Trinity Biotech (NASDAQ:TRIB) Now Covered by StockNews.com

StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research report issued on Wednesday. The firm set a “hold” rating on the stock.

Trinity Biotech Price Performance

Shares of TRIB opened at $0.93 on Wednesday. The stock’s 50-day moving average is $0.93 and its two-hundred day moving average is $1.61. The stock has a market cap of $5.89 million, a PE ratio of -0.41 and a beta of 1.01. Trinity Biotech has a 12 month low of $0.74 and a 12 month high of $3.55.

Hedge Funds Weigh In On Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC increased its holdings in Trinity Biotech plc (NASDAQ:TRIB) by 5.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 378,590 shares of the company’s stock after acquiring an additional 18,780 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent filing with the SEC. 78.97% of the stock is owned by hedge funds and other institutional investors.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.